ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Lindberg, J. [1 ]
De Laere, B. [1 ]
Crippa, A. [1 ]
Eklund, M. [1 ]
Gronberg, H. [1 ]
机构：
[1] Karolinska Inst, Med Epidemiol & Biostat, Stockholm, Sweden
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
基金：
瑞典研究理事会;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
896TiP
引用
收藏
页码：354 / 354
页数：1
相关论文
共 50 条
  • [21] [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
    Hofman, Michael S.
    Emmett, Louise
    Sandhu, Shahneen
    Iravani, Amir
    Joshua, Anthony M.
    Goh, Jeffrey C.
    Pattison, David A.
    Tan, Thean Hsiang
    Kirkwood, Ian D.
    Ng, Siobhan
    Francis, Roslyn J.
    Gedye, Craig
    Rutherford, Natalie K.
    Weickhardt, Andrew
    Scott, Andrew M.
    Lee, Sze-Ting
    Kwan, Edmond M.
    Azad, Arun A.
    Ramdave, Shakher
    Redfern, Andrew D.
    Macdonald, William
    Guminski, Alex
    Hsiao, Edward
    Chua, Wei
    Lin, Peter
    Zhang, Alison Y.
    McJannett, Margaret M.
    Stockler, Martin R.
    Violet, John A.
    Williams, Scott G.
    Martin, Andrew J.
    Davis, Ian D.
    LANCET, 2021, 397 (10276): : 797 - 804
  • [22] Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial
    Corn, Paul G.
    Heath, Elisabeth, I
    Zurita, Amado
    Ramesh, Naveen
    Xiao, Lianchun
    Sei, Emi
    Li-Ning-Tapia, Elsa
    Tu, Shi-Ming
    Subudhi, Sumit K.
    Wang, Jennifer
    Wang, Xuemei
    Efstathiou, Eleni
    Thompson, Timothy C.
    Troncoso, Patricia
    Navin, Nicholas
    Logothetis, Christopher J.
    Aparicio, Ana M.
    LANCET ONCOLOGY, 2019, 20 (10): : 1432 - 1443
  • [23] An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
    Tsuchiya, Tomohiro
    Imanaka, Keiichiro
    Iwaki, Yuki
    Oyama, Ryo
    Hashine, Katsuyoshi
    Yamaguchi, Akito
    Uemura, Hiroji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (12) : 1596 - 1604
  • [24] An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
    Tomohiro Tsuchiya
    Keiichiro Imanaka
    Yuki Iwaki
    Ryo Oyama
    Katsuyoshi Hashine
    Akito Yamaguchi
    Hiroji Uemura
    International Journal of Clinical Oncology, 2019, 24 : 1596 - 1604
  • [25] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
    Alejo Rodriguez-Vida
    Pablo Maroto
    Albert Font
    Cristina Martin
    Begoña Mellado
    Alex Corbera
    Mayra Orrillo
    Oscar Reig
    Rosa Querol
    Alejandro Rios-Hoyo
    Laia Cano
    Judith Alonso
    Gemma Martinez
    Susana Galtes
    Alvaro Taus
    Maria Martinez-Garcia
    Nuria Juanpere
    Oscar Juan
    Joaquim Bellmunt
    British Journal of Cancer, 2023, 128 : 21 - 29
  • [26] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
    Rodriguez-Vida, Alejo
    Maroto, Pablo
    Font, Albert
    Martin, Cristina
    Mellado, Begona
    Corbera, Alex
    Orrillo, Mayra
    Reig, Oscar
    Querol, Rosa
    Rios-Hoyo, Alejandro
    Cano, Laia
    Alonso, Judith
    Martinez, Gemma
    Galtes, Susana
    Taus, Alvaro
    Martinez-Garcia, Maria
    Juanpere, Nuria
    Juan, Oscar
    Bellmunt, Joaquim
    BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 21 - 29
  • [27] Re: [177Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients with Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial
    Adeleke, Sola
    Haroon, Athar
    Kasivisvanathan, Veeru
    EUROPEAN UROLOGY, 2021, 80 (01) : 118 - 119
  • [28] Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
    Antonarakis, Emmanuel S.
    Park, Se Hoon
    Goh, Jeffrey C.
    Shin, Sang Joon
    Lee, Jae Lyun
    Mehra, Niven
    Mcdermott, Ray
    Sala-Gonzalez, Nuria
    Fong, Peter C.
    Greil, Richard
    Retz, Margitta
    Sade, Juan Pablo
    Yanez, Patricio
    Huang, Yi-Hsiu
    Begbie, Stephen D.
    Gafanov, Rustem Airatovich
    De Santis, Maria
    Rosenbaum, Eli
    Kolinsky, Michael P.
    Rey, Felipe
    Chiu, Kun-Yuan
    Roubaud, Guilhem
    Kramer, Gero
    Sumitomo, Makoto
    Massari, Francesco
    Suzuki, Hiroyoshi
    Qiu, Ping
    Zhang, Jinchun
    Kim, Jeri
    Poehlein, Christian H.
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3839 - +
  • [29] GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
    Conduit, Ciara
    Mak, Blossom
    Qu, Wenjia
    Di Lulio, Juliana
    Burder, Ronan
    Bressel, Matthias
    Cusick, Thomas
    Dhillon, Haryana M.
    Lourenco, Richard De Abreu
    Underhill, Craig
    Torres, Javier
    Crumbaker, Megan
    Honeyball, Florian
    Linton, Anthony
    Allen, Ray
    Davis, Ian D.
    Clark, Susan J.
    Horvath, Lisa G.
    Mahon, Kate L.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [30] Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan
    Kosaka, Takeo
    Uemura, Hiroji
    Sumitomo, Makoto
    Harada, Kenichi
    Sugimoto, Mikio
    Hayashi, Narihiko
    Yoshimura, Kazuhiro
    Fukasawa, Satoshi
    Ecstein-Fraisse, Evelyne
    Sunaga, Yoshinori
    Oya, Mototsugu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (08) : 766 - 771
12345